

Alexandre Chan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9284150/publications.pdf>

Version: 2024-02-01

249
papers

5,914
citations

76196

40
h-index

114278

63
g-index

254
all docs

254
docs citations

254
times ranked

7502
citing authors

#	ARTICLE	IF	CITATIONS
1	Validation of pharmaceutical pictograms among older adults with limited English proficiency. Patient Education and Counseling, 2022, 105, 909-916.	1.0	10
2	Investigating how cancer-related symptoms influence work outcomes among cancer survivors: a systematic review. Journal of Cancer Survivorship, 2022, 16, 1065-1078.	1.5	20
3	The use of patient-reported outcomes in routine cancer care: preliminary insights from a multinational scoping survey of oncology practitioners. Supportive Care in Cancer, 2022, 30, 1427-1439.	1.0	27
4	Characteristics associated with inter-individual variability in financial distress in patients with breast cancer prior to and for 12 months following surgery. Supportive Care in Cancer, 2022, 30, 1293-1302.	1.0	4
5	Distinct financial distress profiles in patients with breast cancer prior to and for 12 months following surgery. BMJ Supportive and Palliative Care, 2022, 12, 347-354.	0.8	10
6	Feasibility of Cognitive Training to Promote Recovery in Cancer-Related Cognitive Impairment in Adolescent and Young Adult Patients. Journal of Adolescent and Young Adult Oncology, 2022, 11, 290-296.	0.7	5
7	Impact of coronavirus of 2019 on the delivery of pharmacy services to patients with cancer: An international survey of oncology pharmacy practitioners. Journal of Oncology Pharmacy Practice, 2022, 28, 1832-1847.	0.5	1
8	Reporting adherence, validity and physical activity measures of wearable activity trackers in medical research: A systematic review. International Journal of Medical Informatics, 2022, 160, 104696.	1.6	34
9	Barriers and facilitators to exercise among adult cancer survivors in Singapore. Supportive Care in Cancer, 2022, 30, 4867-4878.	1.0	10
10	Dual contribution of the gut microbiome to immunotherapy efficacy and toxicity: supportive care implications and recommendations. Supportive Care in Cancer, 2022, 30, 6369-6373.	1.0	7
11	Adherence to Cancer Survivorship Care Guidelines and Health Care Utilization Patterns Among Nonmetastatic Breast Cancer Survivors in Singapore. JCO Global Oncology, 2022, 8, e2100246.	0.8	1
12	Implementing a community-based shared care breast cancer survivorship model in Singapore: a qualitative study among primary care practitioners. , 2022, 23, 73.		2
13	Health Disparities in Pharmacy Practice Within the Community: Let's Brainstorm for Solutions. Frontiers in Public Health, 2022, 10, 847696.	1.3	5
14	International society of oncology pharmacy practitioners (ISOPP) position statement: The role of oncology pharmacy practitioners in immunotherapy treatment with immune checkpoint inhibitors for malignant conditions. Journal of Oncology Pharmacy Practice, 2022, , 107815522210901.	0.5	0
15	Diet and exercise advice and referrals for cancer survivors: an integrative review of medical and nursing perspectives. Supportive Care in Cancer, 2022, 30, 8429-8439.	1.0	5
16	Evidence of brain-derived neurotrophic factor in ameliorating cancer-related cognitive impairment: A systematic review of human studies. Critical Reviews in Oncology/Hematology, 2022, 176, 103748.	2.0	9
17	Increased incidence of Pegaspargase-induced hypertriglyceridemia and associated pancreatitis observed in the Hispanic adult patient population. Leukemia and Lymphoma, 2022, 63, 2992-2995.	0.6	4
18	Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. Supportive Care in Cancer, 2021, 29, 2821-2840.	1.0	65

#	ARTICLE	IF	CITATIONS
19	Extracellular Vesicle Proteome of Breast Cancer Patients with and Without Cognitive Impairment Following Anthracycline-based Chemotherapy: An Exploratory Study. <i>Biomarker Insights</i> , 2021, 16, 117727192110182.	1.0	6
20	Clinical and economic evaluation of a surveillance protocol to manage hepatitis B virus (HBV) reactivation among lymphoma patients with resolved HBV infection receiving rituximab. <i>Pharmacotherapy</i> , 2021, 41, 332-341.	1.2	3
21	International Society of Oncology Pharmacy Practitioners (ISOPP) position statement: Role of the oncology pharmacy team in cancer care. <i>Journal of Oncology Pharmacy Practice</i> , 2021, 27, 785-801.	0.5	11
22	Prescribing patterns in breast cancer survivors: A Korean National Health Insurance Service cohort study. <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2021, 59, 358-365.	0.3	0
23	ICES (International Carboplatin Emesis Survey) for the evaluation of the emetogenicity of continuous cycles of carboplatin-based chemotherapy with focus on nausea: A MASCC emesis study group, prospective, observational, real-world multi-centric study.. <i>Journal of Clinical Oncology</i> , 2021, 39, e24086-e24086.	0.8	0
24	Pharmacogenomics Implementation Training Improves Self-Efficacy and Competency to Drive Adoption in Clinical Practice. <i>Frontiers in Pharmacology</i> , 2021, 12, 684907.	1.6	3
25	Distinct employment interference profiles in patients with breast cancer prior to and for 12 months following surgery. <i>BMC Cancer</i> , 2021, 21, 883.	1.1	1
26	Relationship between cytokines and brain-derived neurotrophic factor (BDNF) in trajectories of cancer-related cognitive impairment. <i>Cytokine</i> , 2021, 144, 155556.	1.4	21
27	The efficacy, challenges, and facilitators of telemedicine in post-treatment cancer survivorship care: an overview of systematic reviews. <i>Annals of Oncology</i> , 2021, 32, 1552-1570.	0.6	71
28	Current and Recommended Practices for Evaluating Adverse Drug Events Using Electronic Health Records: A Systematic Review. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2021, 4, 1457.	0.5	4
29	Patient-centric decision framework for treatment alterations in patients with Chemotherapy-induced Peripheral Neuropathy (CIPN). <i>Cancer Treatment Reviews</i> , 2021, 99, 102241.	3.4	29
30	Adverse lifestyle behaviors among childhood cancer survivors with cognitive impairment: The Project Forward Cohort.. <i>Journal of Clinical Oncology</i> , 2021, 39, 138-138.	0.8	0
31	Range, effectiveness, and implementation of decision aids supporting cancer survivors'™ decisions over health services participation in the post-treatment phase: A systematic review.. <i>Journal of Clinical Oncology</i> , 2021, 39, 203-203.	0.8	2
32	Baseline characteristics of breast and gynecological cancer patients enrolled in the trial of a multidisciplinary survivorship care model in an Asian national ambulatory cancer center.. <i>Journal of Clinical Oncology</i> , 2021, 39, 37-37.	0.8	1
33	Cancer-related cognitive impairment is associated with perturbations in inflammatory pathways. <i>Cytokine</i> , 2021, 148, 155653.	1.4	17
34	Pharmacological Treatment of Established Chemotherapy-Induced Peripheral Neuropathy. , 2021, , 155-181.		1
35	Supporting COVID-19 Vaccine Rollout before Charter Class Arrives: The University of California, Irvine Experience. <i>Pharmacy (Basel, Switzerland)</i> , 2021, 9, 164.	0.6	1
36	Older adult and family caregiver experiences with prescription medication labels and their suggestions for label improvement. <i>Exploratory Research in Clinical and Social Pharmacy</i> , 2021, 4, 100087.	0.6	4

#	ARTICLE	IF	CITATIONS
37	24. An analysis of the National Institutes of Health All of Us Research Database: Sociodemographic Disparities Among Patients Who Received Vaccinations. <i>Open Forum Infectious Diseases</i> , 2021, 8, S135-S136.	0.4	0
38	Impact of a pharmacist-led education and follow-up service on anticoagulation control and safety outcomes at a tertiary hospital in China: a randomised controlled trial. <i>International Journal of Pharmacy Practice</i> , 2020, 28, 97-106.	0.3	14
39	Pharmacy students' perceptions toward peer assessment and its use in teaching patient presentation skills. <i>Currents in Pharmacy Teaching and Learning</i> , 2020, 12, 228-236.	0.4	4
40	2019 Update to the American College of Clinical Pharmacy Pharmacotherapy Didactic Curriculum Toolkit. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 2020, 3, 455-464.	0.5	51
41	HPLC-MS/MS coupled with equilibrium dialysis method for quantification of free drug concentration of pazopanib in plasma. <i>Heliyon</i> , 2020, 6, e03813.	1.4	8
42	A study protocol for HEalth-Related quality of life-intervention in survivors of Breast and other cancers experiencing cancer-related fatigue using TraditionAL Chinese Medicine: the HERBAL trial. <i>Trials</i> , 2020, 21, 909.	0.7	4
43	Associations of plasma brain-derived neurotrophic factor (BDNF) and Val66Met polymorphism (rs6265) with long-term cancer-related cognitive impairment in survivors of breast cancer. <i>Breast Cancer Research and Treatment</i> , 2020, 183, 683-696.	1.1	17
44	Preface. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 2-2.	0.5	0
45	Association of mitochondrial DNA content and displacement loop region sequence variations with cancer-related fatigue in breast cancer survivors receiving chemotherapy. <i>Mitochondrion</i> , 2020, 54, 65-71.	1.6	4
46	Psychometric testing of the Functional Assessment of Cancer Therapy/Gynecologic Oncology Group's Neurotoxicity (FACT/GOG-Ntx) subscale in a longitudinal study of cancer patients treated with chemotherapy. <i>Health and Quality of Life Outcomes</i> , 2020, 18, 246.	1.0	27
47	PCN171 COST BURDEN AND WORK OUTCOMES AMONG SINGAPOREAN ADOLESCENT AND YOUNG ADULT CANCER SURVIVORS. <i>Value in Health</i> , 2020, 23, S53.	0.1	0
48	Impact of Cryotherapy on Sensory, Motor, and Autonomic Neuropathy in Breast Cancer Patients Receiving Paclitaxel: A Randomized, Controlled Trial. <i>Frontiers in Neurology</i> , 2020, 11, 604688.	1.1	12
49	1816MO ICES (International Carboplatin Emesis Survey) for the evaluation of the emetogenicity of carboplatin-based chemotherapy with a focus on nausea. MASCC Antiemetic Study Group survey. <i>Annals of Oncology</i> , 2020, 31, S1048-S1049.	0.6	0
50	Assessing biosimilar education needs among oncology pharmacy practitioners worldwide: An ISOPP membership survey. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 11-21.	0.5	5
51	Advances and future directions in the use of mobile health in supportive cancer care: proceedings of the 2019 MASCC Annual Meeting symposium. <i>Supportive Care in Cancer</i> , 2020, 28, 4059-4067.	1.0	17
52	Global oncology pharmacy response to COVID-19 pandemic: Medication access and safety. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 1225-1229.	0.5	12
53	A survey of global biosimilar implementation practice conducted by the International Society of Oncology Pharmacy Practitioners. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 22-32.	0.5	5
54	Cancer survivorship care during COVID-19 perspectives and recommendations from the MASCC survivorship study group. <i>Supportive Care in Cancer</i> , 2020, 28, 3485-3488.	1.0	68

#	ARTICLE	IF	CITATIONS
55	Optimizing Survivorship Care Services for Asian Adolescent and Young Adult Cancer Survivors: A Qualitative Study. <i>Journal of Adolescent and Young Adult Oncology</i> , 2020, 9, 384-393.	0.7	5
56	Self-reported cognitive outcomes among adolescent and young adult patients with noncentral nervous system cancers. <i>Psycho-Oncology</i> , 2020, 29, 1355-1362.	1.0	17
57	Roles and recommendations from primary care physicians towards managing low-risk breast cancer survivors in a shared-care model with specialists in Singapore—a qualitative study. <i>Family Practice</i> , 2020, 37, 547-553.	0.8	9
58	A longitudinal analysis of phenotypic and symptom characteristics associated with inter-individual variability in employment interference in patients with breast cancer. <i>Supportive Care in Cancer</i> , 2020, 28, 4677-4686.	1.0	11
59	Distinct cytokine profiles across trajectories of self-perceived cognitive impairment among early-stage breast cancer survivors. <i>Journal of Neuroimmunology</i> , 2020, 342, 577196.	1.1	9
60	Work- and insurance-related issues among Asian adolescent and young-adult cancer survivors: a qualitative study. <i>Supportive Care in Cancer</i> , 2020, 28, 5901-5909.	1.0	10
61	Role of Exosomes in Cancer-Related Cognitive Impairment. <i>International Journal of Molecular Sciences</i> , 2020, 21, 2755.	1.8	19
62	International Society of Oncology Pharmacy Practitioners global position on the use of biosimilars in cancer treatment and supportive care. <i>Journal of Oncology Pharmacy Practice</i> , 2020, 26, 3-10.	0.5	6
63	Feasibility, delivery, and acceptance of a multidisciplinary survivorship care model based in an Asian national ambulatory cancer center: A six-month review.. <i>Journal of Clinical Oncology</i> , 2020, 38, 34-34.	0.8	1
64	Cost-effectiveness analysis of olanzapine-containing antiemetic therapy for managing highly emetogenic chemotherapy in Southeast Asia: a multinational study. <i>Supportive Care in Cancer</i> , 2019, 27, 1109-1119.	1.0	16
65	Biological predictors of chemotherapy-induced peripheral neuropathy (CIPN): MASCC neurological complications working group overview. <i>Supportive Care in Cancer</i> , 2019, 27, 3729-3737.	1.0	53
66	Optimizing Vancomycin Dosing in Chronic Kidney Disease by Deriving and Implementing a Web-Based Tool Using a Population Pharmacokinetics Analysis. <i>Frontiers in Pharmacology</i> , 2019, 10, 641.	1.6	5
67	An Evaluation of DNA Methyltransferase 1 (DNMT1) Single Nucleotide Polymorphisms and Chemotherapy-Associated Cognitive Impairment: A Prospective, Longitudinal Study. <i>Scientific Reports</i> , 2019, 9, 14570.	1.6	11
68	Risk factors for chemotherapy-induced peripheral neuropathy in patients receiving taxane- and platinum-based chemotherapy. <i>Brain and Behavior</i> , 2019, 9, e01312.	1.0	70
69	Association of plasma leptin, pro-inflammatory adipokines and cancer-related fatigue in early-stage breast cancer patients: A prospective cohort study. <i>Journal of Cellular and Molecular Medicine</i> , 2019, 23, 4281-4289.	1.6	15
70	Prechemotherapy Levels of Plasma Dehydroepiandrosterone and Its Sulfated Form as Predictors of Cancer-Related Cognitive Impairment in Patients with Breast Cancer Receiving Chemotherapy. <i>Pharmacotherapy</i> , 2019, 39, 553-563.	1.2	10
71	Minimal clinically important difference of the EORTC QLQ-CIPN20 for worsening peripheral neuropathy in patients receiving neurotoxic chemotherapy. <i>Supportive Care in Cancer</i> , 2019, 27, 4753-4762.	1.0	25
72	Managing Pharmacotherapy in People Living With HIV and Concomitant Malignancy. <i>Annals of Pharmacotherapy</i> , 2019, 53, 812-832.	0.9	13

#	ARTICLE	IF	CITATIONS
73	Are we mis-estimating chemotherapy-induced peripheral neuropathy? Analysis of assessment methodologies from a prospective, multinational, longitudinal cohort study of patients receiving neurotoxic chemotherapy. <i>BMC Cancer</i> , 2019, 19, 132.	1.1	126
74	Perception of electronic peer review of SOAP notes among pharmacy students enrolling in their first pharmacotherapeutics course. <i>Currents in Pharmacy Teaching and Learning</i> , 2019, 11, 1259-1264.	0.4	6
75	Relationships Between Financial Toxicity and Symptom Burden in Cancer Survivors: A Systematic Review. <i>Journal of Pain and Symptom Management</i> , 2019, 57, 646-660.e1.	0.6	104
76	Replication and Meta-analysis of the Association between BDNF Val66Met Polymorphism and Cognitive Impairment in Patients Receiving Chemotherapy. <i>Molecular Neurobiology</i> , 2019, 56, 4741-4750.	1.9	20
77	Economic burden of adverse drug reactions and potential for pharmacogenomic testing in Singaporean adults. <i>Pharmacogenomics Journal</i> , 2019, 19, 401-410.	0.9	15
78	Management of hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: An observational study. <i>Journal of Oncology Pharmacy Practice</i> , 2019, 25, 1042-1052.	0.5	4
79	Work-related outcomes among cancer survivors in Singapore. <i>Annals of Oncology</i> , 2019, 30, ix134.	0.6	0
80	Distinct and heterogeneous trajectories of self-perceived cognitive impairment among Asian breast cancer survivors. <i>Psycho-Oncology</i> , 2018, 27, 1185-1192.	1.0	42
81	Association of mitochondrial DNA content in peripheral blood with cancer-related fatigue and chemotherapy-related cognitive impairment in early-stage breast cancer patients: a prospective cohort study. <i>Breast Cancer Research and Treatment</i> , 2018, 168, 713-721.	1.1	20
82	Assessment of psychological distress among Asian adolescents and young adults (AYA) cancer patients using the distress thermometer: a prospective, longitudinal study. <i>Supportive Care in Cancer</i> , 2018, 26, 3257-3266.	1.0	33
83	Survivorship care models for breast cancer, colorectal cancer, and adolescent and young adult (AYA) cancer survivors: a systematic review. <i>Supportive Care in Cancer</i> , 2018, 26, 2125-2141.	1.0	22
84	Implementing Clinical Prediction Models: Pushing the Needle Towards Precision Pharmacotherapy. <i>Clinical Pharmacology and Therapeutics</i> , 2018, 103, 180-183.	2.3	9
85	Practitioners' perspectives on community-based breast cancer survivorship care in Singapore: A focus group study. <i>Health and Social Care in the Community</i> , 2018, 26, 404-411.	0.7	5
86	Minimal Clinically Important Difference of the Multidimensional Fatigue Symptom Inventory-Short Form (MFSI-SF) for Fatigue Worsening in Asian Breast Cancer Patients. <i>Journal of Pain and Symptom Management</i> , 2018, 55, 992-997.e2.	0.6	31
87	Cancer Supportive and Survivorship Care in Singapore: Current Challenges and Future Outlook. <i>Journal of Global Oncology</i> , 2018, 4, 1-8.	0.5	17
88	Thalidomide for Delayed Chemotherapy-Induced Nausea and Vomiting: Where Is Its Place in Therapy?. <i>Journal of Clinical Oncology</i> , 2018, 36, 827-828.	0.8	3
89	Impact of Adjuvant Anthracycline-Based and Taxane-Based Chemotherapy on Plasma VEGF Levels and Cognitive Function in Breast Cancer Patients: A Longitudinal Study. <i>Clinical Breast Cancer</i> , 2018, 18, e927-e937.	1.1	15
90	Chemotherapy-associated cognitive impairments in Korean cancer patients: Risk factors and functional outcome. <i>Psycho-Oncology</i> , 2018, 27, 1995-2001.	1.0	5

#	ARTICLE	IF	CITATIONS
91	Impact of brain-derived neurotrophic factor genetic polymorphism on cognition: A systematic review. <i>Brain and Behavior</i> , 2018, 8, e01009.	1.0	73
92	Chemotherapy drug concentrations in hair follicles: a potential biomarker to monitor the effectiveness of scalp cooling for chemotherapy-induced alopecia. <i>Supportive Care in Cancer</i> , 2018, 26, 3669-3670.	1.0	3
93	Psychometric properties and measurement equivalence of the Multidimensional Fatigue Syndrome Inventory- Short Form (MFSI-SF) amongst breast cancer and lymphoma patients in Singapore. <i>Health and Quality of Life Outcomes</i> , 2018, 16, 20.	1.0	9
94	Breast cancer screening behavior, attitude, barriers among middle-aged Chinese women in Macao, China. <i>Journal of Public Health</i> , 2018, 40, e560-e570.	1.0	13
95	A response to the letter to the editor on "Management of hepatitis B reactivation in lymphoma patients on rituximab with past hepatitis B exposure: An observational study". <i>Journal of Oncology Pharmacy Practice</i> , 2018, 24, 478-479.	0.5	1
96	Gut microbiome alterations in breast cancer survivors with cancer-related fatigue.. <i>Journal of Clinical Oncology</i> , 2018, 36, e22178-e22178.	0.8	3
97	Pharmacists' roles in oncology pharmacy services: Results of a global survey. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 185-194.	0.5	37
98	Chemotherapy regimen checks performed by pharmacists contribute to safe administration of chemotherapy. <i>Journal of Oncology Pharmacy Practice</i> , 2017, 23, 18-25.	0.5	21
99	Identifying Potentially Avoidable Readmissions: A Medication-Based 15-Day Readmission Risk Stratification Algorithm. <i>Pharmacotherapy</i> , 2017, 37, 268-277.	1.2	24
100	HbA1c variability in type 2 diabetes is associated with the occurrence of new-onset albuminuria within three years. <i>Diabetes Research and Clinical Practice</i> , 2017, 128, 32-39.	1.1	14
101	Optimizing Symptoms and Management of Febrile Neutropenia among Cancer Patients: Current Status and Future Directions. <i>Current Oncology Reports</i> , 2017, 19, 20.	1.8	5
102	The prognostic performance of adding patient-reported outcomes to the MASCC risk index to identify low-risk febrile neutropenia patients with solid tumors and lymphomas. <i>Supportive Care in Cancer</i> , 2017, 25, 2815-2822.	1.0	5
103	Role of Procalcitonin in Differentiating between Infectious and Noninfectious Fevers among Patients with Lymphoma. <i>Pharmacotherapy</i> , 2017, 37, 908-915.	1.2	3
104	A culturally adapted survivorship programme for Asian early stage breast cancer patients in Singapore: A randomized, controlled trial. <i>Psycho-Oncology</i> , 2017, 26, 1654-1659.	1.0	15
105	Long-term Clinical and Cost Outcomes of a Pharmacist-managed Risk Factor Management Clinic in Singapore: An Observational Study. <i>Clinical Therapeutics</i> , 2017, 39, 2355-2365.	1.1	3
106	A step forward in addressing cancer survivorship in the Asia-Pacific region. <i>BMC Medicine</i> , 2017, 15, 17.	2.3	3
107	Therapeutic Use of Filgrastim for Established Febrile Neutropenia Is Cost Effective Among Patients With Solid Tumors and Lymphomas. <i>Clinical Therapeutics</i> , 2017, 39, 1161-1170.	1.1	2
108	Psychometric properties and measurement equivalence of the English and Chinese versions of the Beck Anxiety Inventory in patients with breast cancer. <i>Supportive Care in Cancer</i> , 2017, 25, 633-643.	1.0	18

#	ARTICLE	IF	CITATIONS
109	2016 Updated MASCC/ESMO consensus recommendations: Emetic risk classification and evaluation of the emetogenicity of antineoplastic agents. <i>Supportive Care in Cancer</i> , 2017, 25, 271-275.	1.0	36
110	2016 Updated MASCC/ESMO Consensus Recommendations: Prevention of Nausea and Vomiting Following High Emetic Risk Chemotherapy. <i>Supportive Care in Cancer</i> , 2017, 25, 277-288.	1.0	103
111	Evaluation of plasma brain-derived neurotrophic factor levels and self-perceived cognitive impairment post-chemotherapy: a longitudinal study. <i>BMC Cancer</i> , 2017, 17, 867.	1.1	28
112	Perceptions and Barriers of Survivorship Care in Asia: Perceptions From Asian Breast Cancer Survivors. <i>Journal of Global Oncology</i> , 2017, 3, 98-104.	0.5	10
113	Applicability of the National Comprehensive Cancer Network/Multinational Association of Supportive Care in Cancer Guidelines for Prevention and Management of Chemotherapy-Induced Nausea and Vomiting in Southeast Asia: A Consensus Statement. <i>Journal of Global Oncology</i> , 2017, 3, 801-813.	0.5	6
114	Mitochondrial DNA content in peripheral blood as a biomarker for cancer-related fatigue in early-stage breast cancer patients: A prospective cohort study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 10018-10018.	0.8	2
115	A genome-wide association study (GWAS) meta-analysis of chemotherapy-associated cognitive impairment (CACI) in Asian early-stage breast cancer patients (ESBC).. <i>Journal of Clinical Oncology</i> , 2017, 35, 10096-10096.	0.8	1
116	A web-based tool to predict chemotherapy-associated cognitive impairment during survivorship.. <i>Journal of Clinical Oncology</i> , 2017, 35, e21609-e21609.	0.8	1
117	Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy. <i>PLoS ONE</i> , 2016, 11, e0148901.	1.1	7
118	Impact of TNF- α (rs1800629) and IL-6 (rs1800795) Polymorphisms on Cognitive Impairment in Asian Breast Cancer Patients. <i>PLoS ONE</i> , 2016, 11, e0164204.	1.1	36
119	Psychometric Properties of the Functional Assessment of Cancer Therapy-“Neutropenia in Asian Cancer Patients With Chemotherapy-Induced Neutropenia. <i>Journal of Pain and Symptom Management</i> , 2016, 52, 428-436.	0.6	3
120	Are adolescent and young adult cancer patients affected by “chemobrain”? a call for evidence. <i>Expert Review of Quality of Life in Cancer Care</i> , 2016, 1, 187-188.	0.6	4
121	Impact of chemotherapy on cancer-related fatigue and cytokines in 1312 patients. <i>Current Opinion in Supportive and Palliative Care</i> , 2016, 10, 165-179.	0.5	19
122	Recommendations for Aligning <sc>PGY</sc>2 Pharmacy Residency Training and Pharmacy Specialist Board Certification. <i>Pharmacotherapy</i> , 2016, 36, e34-9.	1.2	4
123	BSA and ABCB1 polymorphism affect the pharmacokinetics of sunitinib and its active metabolite in Asian mRCC patients receiving an attenuated sunitinib dosing regimen. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 623-632.	1.1	9
124	Underdiagnosis of depression in an economically deprived population in <sc>M</sc>acao, <sc>C</sc>hina. <i>Asia-Pacific Psychiatry</i> , 2016, 8, 70-79.	1.2	8
125	Prevalence and characteristics of adverse drug reactions at admission to hospital: a prospective observational study. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 1636-1646.	1.1	67
126	Medication use by early-stage breast cancer survivors: a 1-year longitudinal study. <i>Supportive Care in Cancer</i> , 2016, 24, 1639-1647.	1.0	3

#	ARTICLE	IF	CITATIONS
127	Exercise improves quality of life in androgen deprivation therapy-treated prostate cancer: systematic review of randomised controlled trials. <i>Endocrine-Related Cancer</i> , 2016, 23, 101-112.	1.6	44
128	Tuberculosis reactivation in a patient receiving anti-programmed death-1 (PD-1) inhibitor for relapsed Hodgkin's lymphoma. <i>Acta Oncologica</i> , 2016, 55, 519-520.	0.8	61
129	Brain-derived neurotrophic factor genetic polymorphism (rs6265) is protective against chemotherapy-associated cognitive impairment in patients with early-stage breast cancer. <i>Neuro-Oncology</i> , 2016, 18, 244-251.	0.6	71
130	Perceptions of pharmacy students and pharmacists on SOAP note education and utility in pharmacy practice. <i>Currents in Pharmacy Teaching and Learning</i> , 2016, 8, 77-82.	0.4	5
131	Personalized Estimate of Chemotherapy-Induced Nausea and Vomiting. <i>Medicine (United States)</i> , 2016, 95, e2476.	0.4	22
132	What are the barriers of quality survivorship care for haematology cancer patients? Qualitative insights from cancer nurses. <i>Journal of Cancer Survivorship</i> , 2016, 10, 122-130.	1.5	18
133	Assessment of mental health literacy in patients with breast cancer. <i>Journal of Oncology Pharmacy Practice</i> , 2016, 22, 437-447.	0.5	16
134	Effect of the CYP3A5 and ABCB1 genotype on exposure, clinical response and manifestation of toxicities from sunitinib in Asian patients. <i>Pharmacogenomics Journal</i> , 2016, 16, 47-53.	0.9	24
135	Incidence and Management of Toxicity Associated with LAsparaginase in the Treatment of ALL and NK/TCCell Lymphoma: an Observational Study. <i>Asian Pacific Journal of Cancer Prevention</i> , 2016, 17, 3155-60.	0.5	2
136	1543 Trajectory of self-perceived cognitive impairment: A 15-month prospective, longitudinal study in Asian early-stage breast cancer (ESBC) patients. <i>European Journal of Cancer</i> , 2015, 51, S218-S219.	1.3	0
137	Survivorship Care Provision for Patients With Hematologic Malignancies. <i>Cancer Nursing</i> , 2015, 38, 414-415.	0.7	2
138	The Effect of Ginger (<i>Zingiber officinale</i>) on Platelet Aggregation: A Systematic Literature Review. <i>PLoS ONE</i> , 2015, 10, e0141119.	1.1	43
139	Association of proinflammatory cytokines and chemotherapy-associated cognitive impairment in breast cancer patients: a multi-centered, prospective, cohort study. <i>Annals of Oncology</i> , 2015, 26, 1446-1451.	0.6	176
140	Economic burden of chemotherapy-induced febrile neutropenia in patients with lymphoma: A systematic review. <i>Critical Reviews in Oncology/Hematology</i> , 2015, 94, 201-212.	2.0	20
141	Metabolism-related pharmacokinetic drug-drug interactions with tyrosine kinase inhibitors: current understanding, challenges and recommendations. <i>British Journal of Clinical Pharmacology</i> , 2015, 79, 241-253.	1.1	114
142	Antiemetic therapy in Asia Pacific countries for patients receiving moderately and highly emetogenic chemotherapy—a descriptive analysis of practice patterns, antiemetic quality of care, and use of antiemetic guidelines. <i>Supportive Care in Cancer</i> , 2015, 23, 273-282.	1.0	27
143	Formation of reactive metabolites and management of tyrosine kinase inhibitor-induced hepatotoxicity: a literature review. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2015, 11, 231-242.	1.5	55
144	A systematic review of patient-reported outcome instruments of dermatologic adverse events associated with targeted cancer therapies. <i>Supportive Care in Cancer</i> , 2015, 23, 2231-2244.	1.0	25

#	ARTICLE	IF	CITATIONS
145	Symptom burden and medication use in adult sarcoma patients. <i>Supportive Care in Cancer</i> , 2015, 23, 1709-1717.	1.0	24
146	Incidence and predictors of anticipatory nausea and vomiting in Asia Pacific clinical practice—a longitudinal analysis. <i>Supportive Care in Cancer</i> , 2015, 23, 283-291.	1.0	31
147	Association of drug exposure with toxicity and clinical response in metastatic renal cell carcinoma patients receiving an attenuated dosing regimen of sunitinib. <i>Targeted Oncology</i> , 2015, 10, 429-437.	1.7	27
148	Baseline patient characteristics, incidence of CINV, and physician perception of CINV incidence following moderately and highly emetogenic chemotherapy in Asia Pacific countries. <i>Supportive Care in Cancer</i> , 2015, 23, 263-272.	1.0	47
149	Rationale and design of the Pan Australasian chemotherapy-induced emesis burden of illness study. <i>Supportive Care in Cancer</i> , 2015, 23, 253-261.	1.0	7
150	Follow-up care practices and barriers to breast cancer survivorship: perspectives from Asian oncology practitioners. <i>Supportive Care in Cancer</i> , 2015, 23, 3193-3200.	1.0	16
151	Systematic review of pharmacologic and non-pharmacologic interventions to manage cognitive alterations after chemotherapy for breast cancer. <i>European Journal of Cancer</i> , 2015, 51, 437-450.	1.3	61
152	Efficacy and Safety of an Attenuated-Dose Sunitinib Regimen in Metastatic Renal Cell Carcinoma: Results From a Prospective Registry in Singapore. <i>Clinical Genitourinary Cancer</i> , 2015, 13, e285-e295.	0.9	21
153	Carotid artery inflammation associated with gemcitabine-based therapy: a special report. <i>Future Oncology</i> , 2015, 11, 2049-2058.	1.1	7
154	Trajectory and risk factors for chemotherapy-induced nausea and vomiting in Asian patients with head and neck cancer. <i>Head and Neck</i> , 2015, 37, 1349-1357.	0.9	7
155	Impact of CINV in earlier cycles on CINV and chemotherapy regimen modification in subsequent cycles in Asia Pacific clinical practice. <i>Supportive Care in Cancer</i> , 2015, 23, 293-300.	1.0	16
156	Clinical Pharmacy Services and Research for Lymphoma Patients at an Asian Cancer Center. <i>Annals of Oncology</i> , 2014, 25, v20.	0.6	0
157	Costs associated with febrile neutropenia in solid tumor and lymphoma patients—an observational study in Singapore. <i>BMC Health Services Research</i> , 2014, 14, 434.	0.9	13
158	Minimum Qualifications for Clinical Pharmacy Practice Faculty. <i>Pharmacotherapy</i> , 2014, 34, e38-44.	1.2	17
159	Vascular endothelial growth factor inhibitors and cognitive impairment: evidence and controversies. <i>Expert Opinion on Drug Safety</i> , 2014, 13, 83-92.	1.0	27
160	Costs and Length of Stay of Drug-Related Hospital Admissions in Cancer Patients. <i>Clinical Therapeutics</i> , 2014, 36, 588-592.	1.1	10
161	Clinical efficacy of adjunctive G-CSF on solid tumor and lymphoma patients with established febrile neutropenia. <i>Supportive Care in Cancer</i> , 2014, 22, 1105-1112.	1.0	10
162	Characteristics of unplanned hospital admissions due to drug-related problems in cancer patients. <i>Supportive Care in Cancer</i> , 2014, 22, 1875-1881.	1.0	29

#	ARTICLE	IF	CITATIONS
163	Role of sunitinib and SU12662 on dermatological toxicities in metastatic renal cell carcinoma patients: in vitro, in vivo, and outcomes investigation. <i>Cancer Chemotherapy and Pharmacology</i> , 2014, 73, 381-388.	1.1	16
164	The genetic variants underlying breast cancer treatment-induced chronic and late toxicities: A systematic review. <i>Cancer Treatment Reviews</i> , 2014, 40, 1199-1214.	3.4	25
165	The changing paradigm for supportive care in cancer patients. <i>Supportive Care in Cancer</i> , 2014, 22, 1441-1445.	1.0	13
166	Technological preferences of aging cancer patients for delivery services and devices to solve drug-related problems in oncology. <i>Supportive Care in Cancer</i> , 2014, 22, 2733-2740.	1.0	5
167	Minimal clinically important difference (MCID) for the functional assessment of cancer therapy: Cognitive function (FACT-Cog) in breast cancer patients. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 811-820.	2.4	94
168	Management options for established chemotherapy-induced peripheral neuropathy. <i>Supportive Care in Cancer</i> , 2014, 22, 2281-2295.	1.0	44
169	A Pilot Study to Evaluate the Role of Therapeutic Drug Monitoring of Pegfilgrastim in Lymphoma Patients Receiving Chemotherapy. <i>Proceedings of Singapore Healthcare</i> , 2014, 23, 13-20.	0.2	3
170	Association between clinical response and toxicities with drug exposure in an alternative dosing regimen of sunitinib. <i>Journal of Clinical Oncology</i> , 2014, 32, 439-439.	0.8	0
171	Potentially inappropriate prescribing and drug-drug interactions among elderly Chinese nursing home residents in Macao. <i>International Journal of Clinical Pharmacy</i> , 2013, 35, 805-812.	1.0	25
172	Breakthrough febrile neutropenia and associated complications among elderly cancer patients receiving myelosuppressive chemotherapy for solid tumors and lymphomas. <i>Supportive Care in Cancer</i> , 2013, 21, 2137-2143.	1.0	14
173	Exploring clinical determinants and anxiety symptom domains among Asian breast cancer patients. <i>Supportive Care in Cancer</i> , 2013, 21, 2185-2194.	1.0	14
174	Acknowledging the relevance of cognitive changes in cancer patients: perspectives of oncology practitioners in Asia. <i>Journal of Cancer Survivorship</i> , 2013, 7, 146-154.	1.5	5
175	Affordability of cancer treatment for aging cancer patients in Singapore: an analysis of health, lifestyle, and financial burden. <i>Supportive Care in Cancer</i> , 2013, 21, 3509-3517.	1.0	26
176	Impact of cancer-related fatigue on chemotherapy-induced nausea and vomiting in Asian cancer patients. <i>Pharmacoepidemiology and Drug Safety</i> , 2013, 22, 1345-1351.	0.9	12
177	Linguistic validation of Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog): methodological concerns. <i>Supportive Care in Cancer</i> , 2013, 21, 655-656.	1.0	10
178	Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC Skin Toxicity Study Group. <i>Supportive Care in Cancer</i> , 2013, 21, 2933-2948.	1.0	203
179	Psychometric Properties and Measurement Equivalence of the English and Chinese Versions of the Functional Assessment of Cancer Therapy-Cognitive in Asian Patients With Breast Cancer. <i>Value in Health</i> , 2013, 16, 1001-1013.	0.1	73
180	Risk of tyrosine kinase inhibitors-induced hepatotoxicity in cancer patients: A meta-analysis. <i>Cancer Treatment Reviews</i> , 2013, 39, 199-206.	3.4	81

#	ARTICLE	IF	CITATIONS
181	Visualizing clinical predictors of febrile neutropenia in Asian cancer patients receiving myelosuppressive chemotherapy. <i>Journal of Oncology Pharmacy Practice</i> , 2013, 19, 111-120.	0.5	12
182	Clinical pharmacy services and research for lymphoma patients at a cancer center. <i>Journal of Oncology Pharmacy Practice</i> , 2013, 19, 24-30.	0.5	13
183	Feasibility and Acceptance of a Pharmacist-Run Tele-oncology Service for Chemotherapy-Induced Nausea and Vomiting in Ambulatory Cancer Patients. <i>Telemedicine Journal and E-Health</i> , 2013, 19, 387-395.	1.6	28
184	Cytokines as Mediators of Chemotherapy-Associated Cognitive Changes: Current Evidence, Limitations and Directions for Future Research. <i>PLoS ONE</i> , 2013, 8, e81234.	1.1	63
185	To SMILE or Not: Supportive Care Matters. <i>Journal of Clinical Oncology</i> , 2012, 30, 1015-1016.	0.8	20
186	Antiemetic Effectiveness and Nausea and Vomiting Incidence During Capecitabine and Oxaliplatin Chemotherapy. <i>Nursing Research</i> , 2012, 61, 405-412.	0.8	5
187	Computational Prediction of State Anxiety in Asian Patients With Cancer Susceptible to Chemotherapy-Induced Nausea and Vomiting. <i>Journal of Clinical Psychopharmacology</i> , 2012, 32, 207-217.	0.7	32
188	Utilizing Mobile Networks for the Detection of Clinically Relevant Interactions Between Chemotherapy Regimens and Complementary and Alternative Medicines. <i>Journal of Alternative and Complementary Medicine</i> , 2012, 18, 165-174.	2.1	9
189	Cognitive changes in multiethnic Asian breast cancer patients: a focus group study. <i>Annals of Oncology</i> , 2012, 23, 2547-2552.	0.6	55
190	Effects of Chemotherapy and Psychosocial Distress on Perceived Cognitive Disturbances in Asian Breast Cancer Patients. <i>Annals of Pharmacotherapy</i> , 2012, 46, 1645-1655.	0.9	41
191	Aprepitant for Patients Receiving Highly Emetogenic Chemotherapy: An Economic Analysis for Singapore. <i>Value in Health Regional Issues</i> , 2012, 1, 66-74.	0.5	10
192	Health State Utility Assessment for Breast Cancer. <i>Value in Health Regional Issues</i> , 2012, 1, 93-97.	0.5	19
193	Economic Evaluation of Anastrozole Versus Tamoxifen for Early Stage Breast Cancer in Singapore. <i>Value in Health Regional Issues</i> , 2012, 1, 46-53.	0.5	9
194	Clinicallyâ€“relevant anticancer-antidepressant drug interactions. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2012, 8, 173-199.	1.5	13
195	Prevalence of the Coprescription of Clinically Important Interacting Drug Combinations Involving Oral Anticancer Agents in Singapore: A Retrospective Database Study. <i>Clinical Therapeutics</i> , 2012, 34, 1696-1704.	1.1	27
196	Clinical Impact of Drugâ€“Drug Interaction Between Aspirin and Prednisolone at a Cancer Center. <i>Clinical Therapeutics</i> , 2012, 34, 2259-2267.	1.1	4
197	Conservative Management of L-Asparaginase-Induced Hypertriglyceridemia in an Adult Patient: A Case Report and Review of the Literature. <i>Onkologie</i> , 2012, 35, 596-598.	1.1	10
198	Assessment of the Relationship Between Adherence with Antiemetic Drug Therapy and Control of Nausea and Vomiting in Breast Cancer Patients Receiving Anthracycline-Based Chemotherapy. <i>Journal of Managed Care Pharmacy</i> , 2012, 18, 385-394.	2.2	33

#	ARTICLE	IF	CITATIONS
199	Incidence of febrile neutropenia among early-stage breast cancer patients receiving anthracycline-based chemotherapy. <i>Supportive Care in Cancer</i> , 2012, 20, 1525-1532.	1.0	44
200	An evaluation on the neuropsychological tests used in the assessment of postchemotherapy cognitive changes in breast cancer survivors. <i>Supportive Care in Cancer</i> , 2012, 20, 1361-1375.	1.0	28
201	Effect of CYP3A4 inducer dexamethasone on hepatotoxicity of lapatinib: clinical and in vitro evidence. <i>Breast Cancer Research and Treatment</i> , 2012, 133, 703-711.	1.1	57
202	Neuro-cognitive impairment in breast cancer patients: Pharmacological considerations. <i>Critical Reviews in Oncology/Hematology</i> , 2012, 83, 99-111.	2.0	38
203	Exploring Chemotherapy-Induced Toxicities through Multivariate Projection of Risk Factors: Prediction of Nausea and Vomiting. <i>Toxicological Research</i> , 2012, 28, 81-91.	1.1	9
204	AIDS-related lymphoma (ARL) in Asians in the era of HAART and rituximab.. <i>Journal of Clinical Oncology</i> , 2012, 30, e18546-e18546.	0.8	0
205	Clinical outcomes for cancer patients using complementary and alternative medicine. <i>Alternative Therapies in Health and Medicine</i> , 2012, 18, 12-7.	0.0	6
206	Development of a chemotherapy regimen interaction database for the mobile internet: detecting interactions with psychotropics through OncoRx-MI. <i>Informatics for Health and Social Care</i> , 2011, 36, 132-146.	1.4	4
207	P43 Efficacy of antiemetics in patients receiving XELOX “ A single-centre, prospective study. <i>European Journal of Cancer</i> , Supplement, 2011, 9, 17.	2.2	1
208	3072 POSTER Impact of Adherence to Antiemetic Regimens on Outcome of Nausea and Vomiting Control Among Asian Breast Cancer Patients Receiving Anthracycline-based Chemotherapy. <i>European Journal of Cancer</i> , 2011, 47, S243-S244.	1.3	1
209	Polypharmacy in elderly patients with cancer: clinical implications and management. <i>Lancet Oncology</i> , The, 2011, 12, 1249-1257.	5.1	208
210	Clinically relevant drug interactions between anticancer drugs and psychotropic agents. <i>European Journal of Cancer Care</i> , 2011, 20, 6-32.	0.7	46
211	Comparison of daily filgrastim and pegfilgrastim to prevent febrile neutropenia in Asian lymphoma patients. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 75-81.	0.7	16
212	Management of tumor lysis syndrome with a single fixed dose of rasburicase in Asian lymphoma patients: A case series and literature review. <i>Asia-Pacific Journal of Clinical Oncology</i> , 2011, 7, 351-356.	0.7	11
213	Dosing modifications of targeted cancer therapies in patients with special needs: Evidence and controversies. <i>Critical Reviews in Oncology/Hematology</i> , 2011, 81, 58-74.	2.0	3
214	Impact of colony-stimulating factors to reduce febrile neutropenic events in breast cancer patients receiving docetaxel plus cyclophosphamide chemotherapy. <i>Supportive Care in Cancer</i> , 2011, 19, 497-504.	1.0	46
215	How well does the MESTT correlate with CTCAE scale for the grading of dermatological toxicities associated with oral tyrosine kinase inhibitors?. <i>Supportive Care in Cancer</i> , 2011, 19, 1667-1674.	1.0	28
216	Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. <i>Supportive Care in Cancer</i> , 2011, 19, 1079-1095.	1.0	374

#	ARTICLE	IF	CITATIONS
217	Electronic database to detect drug-drug interactions between antidepressants and oral anticancer drugs from a cancer center in Singapore: implications to clinicians. <i>Pharmacoepidemiology and Drug Safety</i> , 2011, 20, 939-947.	0.9	13
218	Impact of erythropoiesis-stimulating agent prescribing at an Asian cancer center, after release of safety advisories. <i>Journal of Oncology Pharmacy Practice</i> , 2011, 17, 350-359.	0.5	0
219	Breakthrough Febrile Neutropenia and Associated Complications in Non-Hodgkin's Lymphoma Patients Receiving Pegfilgrastim. <i>Acta Haematologica</i> , 2011, 125, 107-114.	0.7	17
220	Preventing Oxaliplatin-Induced Sensory Neurotoxicity: A Methodology Perspective. <i>Journal of Clinical Oncology</i> , 2011, 29, e489-e489.	0.8	0
221	An onco-informatics database for anticancer drug interactions with complementary and alternative medicines used in cancer treatment and supportive care: an overview of the OncoRx project. <i>Supportive Care in Cancer</i> , 2010, 18, 883-891.	1.0	24
222	A prospective study to evaluate the feasibility and economic benefits of rapid infusion rituximab at an Asian cancer center. <i>International Journal of Hematology</i> , 2010, 91, 826-830.	0.7	28
223	Opinions on Drug Interaction Sources in Anticancer Treatments and Parameters for an Oncology-Specific Database by Pharmacy Practitioners in Asia. <i>Health Services Insights</i> , 2010, 3, HSI.S3679.	0.6	7
224	Clinically-Relevant Chemotherapy Interactions with Complementary and Alternative Medicines in Patients with Cancer. <i>Recent Patents on Food, Nutrition & Agriculture</i> , 2010, 2, 12-55.	0.5	13
225	Drug-Drug Interactions between Oral Antiepileptics and Oral Anticancer Drugs: Implications to Clinicians. <i>European Neurology</i> , 2010, 64, 88-94.	0.6	8
226	OncoRx-IQ: a tool for quality assessment of online anticancer drug interactions. <i>International Journal for Quality in Health Care</i> , 2010, 22, 93-106.	0.9	14
227	Detection and management of oncology drug interactions: Can we do better?. <i>Maturitas</i> , 2010, 65, 181-182.	1.0	5
228	Cancer informatics for the clinician: An interaction database for chemotherapy regimens and antiepileptic drugs. <i>Seizure: the Journal of the British Epilepsy Association</i> , 2010, 19, 59-67.	0.9	8
229	Harnessing the internet cloud for managing drug interactions with chemotherapy regimens in patients with cancer suffering from depression. <i>Acta Oncologica</i> , 2010, 49, 1235-1245.	0.8	12
230	Clinically-Relevant Chemotherapy Interactions with Complementary and Alternative Medicines in Patients with Cancer. <i>Recent Patents on Food, Nutrition & Agriculture</i> , 2010, 2, 12-55.	0.5	17
231	Clinical predictors for emesis in breast cancer patients receiving anthracycline-based chemotherapy: Do Asians measure up?. <i>Journal of Clinical Oncology</i> , 2010, 28, e19603-e19603.	0.8	0
232	Patients' perspectives and safe handling of oral anticancer drugs at an Asian cancer center. <i>Journal of Oncology Pharmacy Practice</i> , 2009, 15, 161-165.	0.5	20
233	Complementary and alternative medicine (CAM) usage in Singaporean adult cancer patients. <i>Annals of Oncology</i> , 2009, 20, 752-757.	0.6	79
234	Clinical Predictors of Chemotherapy-Induced Nausea and Vomiting in Breast Cancer Patients Receiving Adjuvant Doxorubicin and Cyclophosphamide. <i>Annals of Pharmacotherapy</i> , 2009, 43, 444-452.	0.9	59

#	ARTICLE	IF	CITATIONS
235	Evidence-Based Treatment Options for the Management of Skin Toxicities Associated with Epidermal Growth Factor Receptor Inhibitors. <i>Annals of Pharmacotherapy</i> , 2009, 43, 1658-1666.	0.9	44
236	Evaluation of Thiazolidinediones on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus: A Systematic Review. <i>Journal for Nurse Practitioners</i> , 2009, 5, 176-184.	0.4	0
237	Clinically significant drug-drug interactions between oral anticancer agents and nonanticancer agents: A delphi survey of oncology pharmacists. <i>Clinical Therapeutics</i> , 2009, 31, 2379-2386.	1.1	51
238	Late-onset neutropenia following RCHOP chemotherapy in diffuse large B-cell lymphoma. <i>American Journal of Hematology</i> , 2009, 84, 414-417.	2.0	44
239	Improving pharmaceutical care in oncology by pharmacoinformatics: the evolving role of informatics and the internet for drug therapy. <i>Lancet Oncology</i> , The, 2009, 10, 1011-1019.	5.1	19
240	Clinically Significant Drug-Drug Interactions Between Oral Anticancer Agents and Nonanticancer Agents: Profiling and Comparison of Two Drug Compendia. <i>Annals of Pharmacotherapy</i> , 2008, 42, 1737-1748.	0.9	68
241	Drug interactions between chemotherapeutic regimens and antiepileptics. <i>Clinical Therapeutics</i> , 2008, 30, 1385-1407.	1.1	141
242	Evolving roles of oncology pharmacists in Singapore: A survey on prescribing patterns of antiemetics for chemotherapy induced nausea and vomiting (CINV) at a cancer centre. <i>Journal of Oncology Pharmacy Practice</i> , 2008, 14, 23-29.	0.5	23
243	Liposomal doxorubicin-associated acute hypersensitivity despite appropriate preventive measures. <i>Journal of Oncology Pharmacy Practice</i> , 2007, 13, 105-107.	0.5	17
244	Systemic Anticoagulant Prophylaxis for Central Catheter-Associated Venous Thrombosis in Cancer Patients. <i>Annals of Pharmacotherapy</i> , 2007, 41, 635-641.	0.9	20
245	Survey of topical oral solutions for the treatment of chemo-induced oral mucositis. <i>Journal of Oncology Pharmacy Practice</i> , 2005, 11, 139-143.	0.5	44
246	Experience with nesiritide at a community hospital. <i>American Journal of Health-System Pharmacy</i> , 2004, 61, 1337-1338.	0.5	2
247	Pulmonary Edema and Possible Pneumonitis Associated with Celecoxib. <i>Annals of Pharmacotherapy</i> , 2004, 38, 1086-1086.	0.9	1
248	Worldwide Characteristics and Trends of Pharmacist Interventions Contributed to Minimize Health Disparities. <i>JACCP Journal of the American College of Clinical Pharmacy</i> , 0, , .	0.5	0
249	Decision aids for cancer survivors' engagement with survivorship care services after primary treatment: a systematic review. <i>Journal of Cancer Survivorship</i> , 0, , .	1.5	1